Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β‐cells in db/db mice: The earlier and longer, the better
Diabetes, Obesity and Metabolism, EarlyView.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Tomohiko
Kimura
MD
,
Atsushi
Obata
MD
,
Masashi
Shimoda
MD
,
Seizo
Okauchi
MD
,
Yukiko
Kanda ‐Kimura
MD
,
Yuka
Nogami
MSc
,
Saeko
Moriuchi
MSc
,
Hidenori
Hirukawa
MD
,
Kenji
Kohara
MD
,
Shuhei
Nakanishi
MD
,
Tomo Source Type: research
More News: Diabetes | Eating Disorders & Weight Management | Endocrinology | Obesity | Pancreas | SGLT2 Inhibitors